Intolerance to 5-aminosalicylate is a risk of poor prognosis in ulcerative colitis patients

被引：0
|
作者：
Fujii, T. [1 ]
Hibiya, S. [1 ]
Maeyashiki, C. [2 ]
Saito, E. [1 ]
Takenaka, K. [1 ]
Motobayashi, M. [1 ]
Shimizu, H. [1 ]
Nagahori, M. [1 ]
Ohtsuka, K. [1 ]
Kurosaki, M. [2 ]
Yauchi, T. [3 ]
Watanabe, M. [1 ]
机构：
[1] Tokyo Med & Dent Univ, Dept Gastroenterol & Hepatol, Tokyo, Japan
[2] Musashino Red Cross Hosp, Gastroenterol, Tokyo, Japan
[3] Soka Municipal Hosp, Gastroenterol, Soka, Japan
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P461
引用
收藏
页码：S409 / S410
页数：2
相关论文
共 50 条
  • [31] Trends of 5-Aminosalicylate Medication Use in Patients With Crohn Disease
    Noureldin, Mohamed
    Cohen-Mekelburg, Shirley
    Mahmood, Asadullah
    Stidham, Ryan
    Higgins, Peter D. R.
    Govani, Shail
    Deshpande, Amar R.
    Waljee, Akbar K.
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (04) : 516 - 521
  • [32] A chromatographic approach to development of 5-aminosalicylate/folic acid fixed-dose combinations for treatment of Crohn's disease and ulcerative colitis
    Jelicic, Mario-Livio
    Brusac, Edvin
    Klaric, Daniela Amidzic
    Nigovic, Biljana
    Turk, Niksa
    Mornar, Ana
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [33] A chromatographic approach to development of 5-aminosalicylate/folic acid fixed-dose combinations for treatment of Crohn’s disease and ulcerative colitis
    Mario-Livio Jeličić
    Edvin Brusač
    Daniela Amidžić Klarić
    Biljana Nigović
    Nikša Turk
    Ana Mornar
    Scientific Reports, 10
  • [34] Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with mild-to-moderate ulcerative colitis.
    Jeon, S.
    Lee, H.
    Hong, S.
    Kim, T.
    Kim, W.
    Cheon, J.
    INFLAMMATORY BOWEL DISEASES, 2011, 17 : S47 - S48
  • [35] 5-aminosalicylate drugs generate anti-inflammatory hydroxy fatty acids that act upon macrophages to promote inflammation resolution in ulcerative colitis
    Wysoczanski, R.
    Kendall, A. C.
    Motwani, M.
    Vega, R.
    Rahman, F. Z.
    McCartney, S.
    Bloom, S. L.
    Nicolaou, A.
    Gilroy, D. W.
    Segal, A. W.
    Marks, D. J.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2017, 47 : 50 - 51
  • [36] LACTOSE INTOLERANCE IN JEWISH PATIENTS WITH ULCERATIVE COLITIS
    TANDON, R
    MANDELL, H
    SPIRO, HM
    THYER, WR
    AMERICAN JOURNAL OF DIGESTIVE DISEASES, 1971, 16 (09): : 845 - &
  • [37] Efficacy of topical versus oral 5-aminosalicylate for treatment of 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats
    Li, Jin
    Chen, Cheng
    Cao, Xiao-nian
    Wang, Gui-hua
    Hu, Jun-bo
    Wang, Jing
    JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES, 2014, 34 (01) : 59 - 65
  • [38] Efficacy of topical versus oral 5-aminosalicylate for treatment of 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats
    Jin Li
    Cheng Chen
    Xiao-nian Cao
    Gui-hua Wang
    Jun-bo Hu
    Jing Wang
    Journal of Huazhong University of Science and Technology [Medical Sciences], 2014, 34 : 59 - 65
  • [39] Efficacy of Topical versus Oral 5-Aminosalicylate for Treatment of 2,4,6-Trinitrobenzene Sulfonic Acid-induced Ulcerative Colitis in Rats
    李进
    陈成
    曹小年
    王桂华
    胡俊波
    王晶
    Current Medical Science, 2014, (01) : 59 - 65
  • [40] A practical perspective on ulcerative colitis: Patients' needs from aminosalicylate therapies
    Loftus, Edward V., Jr.
    INFLAMMATORY BOWEL DISEASES, 2006, 12 (12) : 1107 - 1113
12345